Luis Gonzalez
Cardiology · West New York, NJNPI 1225199698
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Johnson & Johnson at 30.4% of the total. Reporting peaked in 2019 at $605 and has fallen 60.6% since, to $238 in 2025. That places this record below the midpoint for cardiology clinicians in NJ, where the typical reported total is $1,485.
Across 75 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$378
- Medtronic$178
- ANI Pharmaceuticals, Inc.$174
- Novartis$95
- Gilead$69
- Eyepoint US, Inc.$60
- plus $288 from 11 others
Across 4 payments — averaging $2263.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$9K
What the payments were for
- Food & beverage$1,22198%
- Education$222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $378 |
| Medtronic | 2 | $178 |
| ANI Pharmaceuticals, Inc. | 11 | $174 |
| Novartis | 7 | $95 |
| Gilead | 5 | $69 |
| Eyepoint US, Inc. | 2 | $60 |
| Merck | 2 | $53 |
| Apellis Pharmaceuticals, Inc. | 2 | $38 |
| Pfizer | 3 | $38 |
| Harrow Eye, LLC | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
| Boston Scientific | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Viva$159
How this compares
$1,243 in reported general payments places this provider in the 45th percentile of 31 cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 237 | $261,062 |
| EntrestoSacubitril/Valsartan | 87 | $107,234 |
| JardianceEmpagliflozin | 80 | $82,877 |
| XareltoRivaroxaban | 61 | $56,745 |
| Olmesartan Medoxomil | 383 | $27,749 |
| EliquisApixaban | 26 | $25,598 |
| JanuviaSitagliptin Phosphate | 14 | $13,873 |
| VascepaIcosapent Ethyl | 26 | $12,847 |
| Metoprolol Succinate | 477 | $12,782 |
| DapagliflozinDapagliflozin Propanediol | 13 | $10,138 |
| Atorvastatin Calcium | 320 | $5,960 |
| Candesartan Cilexetil | 65 | $5,796 |
| Telmisartan | 105 | $3,999 |
| Rosuvastatin Calcium | 84 | $3,843 |
| Amlodipine Besylate | 370 | $3,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $14 | $261,062237 claims |
| NovartisEntresto | $95 | $107,23487 claims |
| Boehringer IngelheimJardiance | $15 | $82,87780 claims |
| Johnson & JohnsonXarelto | $378 | $56,74561 claims |
| PfizerEliquis | $38 | $25,59826 claims |
| MerckJanuvia | $53 | $13,87314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 31 cardiology providers in New Jersey.
Other cardiology in West New York
- Michael SchwarzRutherford$40K
- Beverly DemchukOcean$12K
- Lei XuBrown Hills$10K
- Sarika SharmaRochelle Park$9K
- Vasant Paul KateBrick$7K
- Pragnesh GadhviUnion City$7K
- Ebrahim IssaTeaneck$5K
- Ricardo CalvoEdison$5K
- Marc ColmerNeptune$5K
- Ian MolkEdison$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.